Novo Nordisk (NOVOB.DK) shares are losing 20% after the pharmaceutical giant, known for its obesity drugs Ozempic and Wegova, released disappointing clinical trial data for its experimental obesity drug CagriSema. Patients treated with Novo's next-generation weight-loss drug CagriSema lost an average of 22.7% of their weight after 68 weeks, falling short of the 25% goal the drugmaker expected. About 40% of patients lost 25% or more of their body weight.
The company's shares are trading at their lowest since August 2023. Source: xStation
Nasdaq, āļāļāļāļāļģ āđāļĨāļ°āđāļāļīāļāļāļļāđāļāļāļķāđāļ āļŦāļĨāļąāļ Fed āļāļķāđāļāļāļāļāđāļāļĩāđāļĒ
Nasdaq 100 āļāļĢāļąāļāļāļķāđāļ 1.7%
āļāđāļēāļ§āđāļāđāļāļ§āļąāļāļāļĩāđ 18 āļ.āļĒ.
ð JB Hunt āļĢāđāļ§āļ 13% āļāđāļāļāļļāļāļāđāļģāļĄāļąāļāļāļāļāļąāļāļŦāļļāđāļāļāļāļŠāđāļāļŠāļŦāļĢāļąāļāļŊ